RE:Stock price correction.Just saw that Aurora just achieved its first positive adjusted EBITDA, largely because its medical cannabis segment was up 15% YoY. That is significant, especially prior to the Parliamentary Committee's upcoming recommendations on the Cannabis Act. If the government could just get out of the way, LABS, ACB and TLRY could have the stars align for them early 2024. I might have to break my own rule of investing no more than 5% in a spec stock... these prices won't last forever.